Connect
← Return to new study on cardiovascular risk of ADT
Discussion
new study on cardiovascular risk of ADT
Prostate Cancer | Last Active: May 8 6:10am | Replies (16)Comment receiving replies
Very interesting study, Definitely concerns me that I was on Lupron for so long.
You have quoted one paragraph within the article. I think this following paragraph really describes what they’ve found with Orgovyx creating much less plaque than Lupron
Conclusions and Relevance In this randomized clinical trial in men with localized PCa treated with radiation plus ADT, the GnRH agonist leuprolide was associated with greater coronary plaque progression within 12 months compared with the GnRH antagonist relugolix. This change was driven by an increase in noncalcified plaque volume and may be mediating ADT-associated CV risk.
Really glad you brought this up.
Replies to "Very interesting study, Definitely concerns me that I was on Lupron for so long. You have..."
Connect
@jeffmarc
Another thing that caught my attention was that the researchers were seeing coronary plaque progression within only 12 months of ADT therapy.
I hope this study gets attention with oncologists, despite the fact that it was published in a cardiology journal. I suspect the researchers will give several talks and presentations to reach a wider audience. But hopefully sharing it here too will raise awareness. I know the lower cardiovascular risk of Orgovyx has been discussed several times in the forum, but this study really provides sound scientific evidence for that.